Skip to Main Content

Try STAT+ TODAY

diabetes

Most Read

Biotech Matthew Herper

FDA approves Lilly diabetes drug that analysts expect to be a big seller

Health Isabella Cueto

Black, Hispanic, and Asian Americans should be screened at lower BMI for diabetes, study says

Politics Rachel Cohrs

Would drugmakers lower their insulin prices if Congress asks nicely?

Biotech Matthew Herper

With new diabetes drug data, Eli Lilly is taking aim at obesity

First Opinion Gary Taubes

How a ‘fatally, tragically flawed’ paradigm has derailed the science of obesity

STAT Madness Rebecca Sohn

Researchers pursuing novel treatments for herpes infections and diabetes win STAT Madness

Health Elizabeth Cooney

Why people with diabetes are being hit so hard by Covid-19

Politics Nicholas Florko

‘Everyone is at fault’: With insulin prices skyrocketing, there’s plenty of blame to go around

All Coverage

Health Edward Chen

As diabetes during pregnancy grows more common, experts point to a need for preventive care

Health Akila Muthukumar

Popular drug may have new benefit in men with diabetes, but not women, study shows

advertisement

Health Tech Katie Palmer

With new research, health tech companies try to make a case for virtual diabetes care

Pharmalot Ed Silverman

Pharmalittle: Cancer coalition aims to boost access to meds in poor countries; Moderna’s vaccine patent defense poses shield for others

Pharmalot Ed Silverman

Pharmalittle: Investors reject proposals for Covid vaccine makers to share know-how; CMS head says Alzheimer’s drug decision is rare

Politics Nicholas Florko

Human Rights Watch says unaffordable U.S. insulin is a human rights abuse

Politics Rachel Cohrs

New bipartisan insulin policy aims to entice drugmakers to lower prices

The Readout LOUD Adam Feuerstein and Meg Tirrell

Listen: What’s next for Roche, a debate over second boosters, & Vertex’s recent success

Exclusive Matthew Herper

Douglas Melton, noted stem cell researcher, leaves Harvard for Vertex to create diabetes treatments

First Opinion Podcast Patrick Skerrett

Listen: The ‘underground market’ for insulin and diabetes supplies

Pharmalot Ed Silverman

Civica Rx has an ambitious plan to make low-cost insulin for all Americans. But can it work?

First Opinion Alina Bills

Turning to social media to get affordable insulin: a clear sign of a broken health care system

Pharmalot Ed Silverman

Michigan attorney general pursues investigation into Lilly’s ‘grossly’ excessive insulin prices

Health Tech Katie Palmer

For digital diabetes care, is more data always better?

Health Tech Katie Palmer

Medicine’s first autonomous AI could prevent blindness due to diabetes — if it can reach those most in need

Health Tech Katie Palmer

Carbon Health launches a program for continuous glucose monitoring to curb diabetes risk

Pharmalot Ed Silverman

Lilly cuts the wholesale price on some insulin products, but impact is likely to be limited

Health Elizabeth Cooney

As diabetes prevalence rises in children and adults, screening age drops to 35 for overweight adults

Health Tech Katie Palmer

Artificial pancreases were a breakthrough for type 1 diabetes. The research in type 2 is just beginning

Pharmalot Ed Silverman

Insulin makers and pharmacy benefit managers must face racketeering claims in a lawsuit

Health Tech Katie Palmer

Demand is growing for continuous glucose monitoring for type 2 diabetes. Primary care doctors need to prepare

Pharmalot Ed Silverman

‘This is not enough’: Walmart’s plan to sell another private label insulin is met with skepticism

Health Tech Katie Palmer

Experts debate the value of digital coaching for type 2 diabetes

Exclusive Erin Brodwin

Onduo’s new exec on Google’s data skills, real-world evidence, and moving the needle on outcomes

Exclusive Erin Brodwin

Carbon Health dives into digital diabetes care with virtual clinic acquisition